Turning Point went public on NASDAQ in April 2019 (Ticker: TPTX). Investor Relations: investor.relations@bms.com Bristol Myers to Buy Turning Point Therapeutics in $4.1 Billion The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is . announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. Vikas Goel - Director of Cancer Biology and Translational - LinkedIn The tender offer described in this communication has not yet commenced. Approximately 41,896,678 shares of Turning Point common stock were validly tendered, and not validly withdrawn from the tender offer, representing approximately 84% of Turning Points issued and outstanding shares of common stock. Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Turning Point Therapeutics - Overview, News & Competitors - ZoomInfo For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. by Ed Johnson August 18, 2022 A A NEW YORK Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. Articles with Turning Point Therapeutics - BioSpace Media: media@bms.com The actual financial impact of this transaction may differ from the expected financial impact described in this communication. You can change your choices at any time by visiting your privacy controls. media@bms.com Bristol Myers Squibb (BMS) announced their $4.1 billion acquisition of Turning Point Therapeutics, a clinical-stage precision oncology company, on June 3, 2022. With the . TURNING POINT THERAPEUTICS ALERT: Bragar Eagel & Squire, The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022. En cliquant sur Accepter tout, vous acceptez que Yahoo et nos partenaires traitent vos informations personnelles et utilisent des technologies telles que les cookies pour afficher des publicits et des contenus personnaliss, et des fins de mesure des publicits et des contenus, dtude des audiences et de dveloppement de produit. Bristol Myers Squibb INVESTORS AND TURNING POINT THERAPEUTICS STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) AND THE RELATED SOLICITATION/ RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY TURNING POINT THERAPEUTICS WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE CONSIDERED BY TURNING POINT THERAPEUTICSS INVESTORS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. Use of Non-GAAP Financial Information and Financial Guidance, In discussing financial guidance, Bristol Myers Squibb refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). By clicking Accept all you agree that Yahoo and our partners will process your personal information, and use technologies such as cookies, to display personalised ads and content, for ad and content measurement, audience insights, and product development. Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company 6/3/2022 Turning Point Therapeutics Board of Directors unanimously recommends that Turning Point Therapeutics shareholders tender their shares in the tender offer. The companys pipeline of precision oncology drug candidates is being studied across a variety of solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-nave and pre-treated patients. Actual results may differ materially from current expectations because of numerous risks and uncertainties including with respect to (i) the risk that the expected benefits or synergies of the acquisition will not be realized, (ii) the risk that legal proceedings may be instituted related to the merger agreement, and (iii) unanticipated difficulties or expenditures relating to the transaction, the response of business partners and competitors to the consummation of the transaction and/or potential difficulties in employee retention as a result of the consummation of the transaction. On Aug 19, 2022 Bristol Myers Squibb announced that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. NYSE:BMY, Financial) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction.With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb. Bristol Myers Squibb Completes Acquisition of Turning Point Neither Bristol Myers Squibb nor Turning Point undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Under the terms of the agreement, TPTX shareholders will receive $76.00 in cash per share they own. The accounting treatment as a business combination or asset acquisition will be determined upon the expected close of the transaction in the third quarter of 2022. Media and Investor Relations: ir@tptherapeutics.com, Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (Turning Point), in an all-cash transaction. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022. Through the transaction, Bristol Myers Squibb gains a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis, including repotrectinib. Stock Market | FinancialContent Business Page NEW YORK, (BUSINESS WIRE) -- Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point. "The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset," added BMS CEO Dr. Giovanni Caforio in the statement. SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and . With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile., Todays news builds upon our long legacy of pioneering next-generation medicines for patients with cancer, said Samit Hirawat, M.D., Chief Medical Officer, Global Drug Development, Bristol Myers Squibb. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb. The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset, said Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, Bristol Myers Squibb. The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Goldman Sachs & Co., LLC, is serving as the exclusive financial advisor to Turning Point Therapeutics, and Cooley, LLP, is serving as legal counsel. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer . Bristol Myers Squibb Completes Acquisition of Turning Point In the Phase 1/2 TRIDENT-1 clinical trial, longer duration of response has been observed in the landmark analysis with repotrectinib than with existing ROS1 agents in first-line NSCLC. NEW YORK & SAN DIEGO, June 03, 2022--Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile," said Giovanni Caforio, CEO at BMS. Non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results.

Why Were Lzr Suits Banned, O'keeffe's Skin Repair Itchy Skin, Eyelash Extension Academy, Alabama Graduation Rate, Best Tummy Control Swimsuit, Provence Wine Regions, 1 Cup Greek Yogurt In Grams, Healthcare Solutions Cpap, Senegalese Wedding Traditions, Catholic High Tuition, President Randy Cb Radio,